In Q1 FY2026 (ended March 31, 2026), Organon reported revenue of $1.46 billion, down 3.5% year-over-year. Net income rose 67.8% to $146 million, and diluted EPS increased 66.7% to $0.55. The company held $1.12 billion in cash, $903 million in equity, and $8.57 billion in long-term debt.
•Revenue decreased 3.5% YoY to $1.46 billion.
•Net income surged 67.8% to $146 million.
•Diluted EPS grew 66.7% to $0.55.
•Long-term debt stood at $8.57 billion as of March 31, 2026.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices globally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive.
Its portfolio also includes NuvaRing, a monthly vaginal contraceptive ring, Cerazette, Marvelon, and Mercilon to prevent pregnancy, Follistim AQ, which is used to promote development of ovarian follicles, Elonva, a follicle stimulant, Ganirelix acetate injection, an injectable antagonist, Jada for abnormal postpartum uterine bleeding and hemorrhage, and Xaciato for bacterial vaginosis.
Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima. Its portfolio also includes oncology products, including Ontruzant and Aybintio, Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies, and Poherdy, a neu receptor antagonist
Cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands. Its portfolio also includes Cozaar and Hyzaar for hypertension, and respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands
Seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. Additionally, it provides dermatology products under the Vtama, Diprosone, and Elocon brand. Its portfolio also includes bone health products under the Fosamax brand, non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands Proscar for symptomatic benign prostatic hyperplasia, and Propecia for male pattern hair loss.
The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and institutions. Founded in 1923, Organon & Co. is headquartered in Jersey City, New Jersey.
Organon & Co. is a healthcare company focused on developing and delivering women's health solutions globally. Its women's health portfolio includes contraception and fertility products such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; and Follistim AQ, used to promote ovarian follicle development. The company also offers Jada for abnormal postpartum uterine bleeding and Xaciato for bacterial vaginosis. Beyond women's health, Organon has a biosimilars portfolio with immunology products like Brenzys, Renflexis, and Hadlima, as well as oncology products including Ontruzant and Aybintio. Additionally, it markets cholesterol-modifying medicines under brands like Zetia and Vytorin, hypertension treatments such as Cozaar and Hyzaar, respiratory products like Singulair and Dulera, dermatology products including Vtama, bone health products under Fosamax, and non-opioid pain management options like Arcoxia.
Where is Organon & Co. (OGN) listed and in which currency?
Organon & Co. is listed on the New York Stock Exchange (NYSE) under the ticker symbol OGN. Its shares are traded in US dollars (USD), reflecting its primary listing in the United States. The company's financial reporting and stock price are denominated in USD, making it accessible to investors on major US exchanges.
What sector and industry does Organon & Co. (OGN) belong to?
Organon & Co. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. This classification indicates that the company is primarily involved in the research, development, and manufacturing of pharmaceutical drugs. As a drug manufacturer, Organon produces a wide range of prescription therapies and medical devices, with a strong emphasis on women's health, biosimilars, and other therapeutic areas such as oncology, cardiovascular, respiratory, and dermatology.
Where is Organon & Co. (OGN) headquartered and what markets does it serve?
Organon & Co. is headquartered in the United States, as indicated by its country of incorporation. The company operates globally, delivering women's health solutions through prescription therapies and medical devices worldwide. Its products are marketed across various regions, including the US and international markets. The company's global reach is evident from its diverse portfolio, which includes brands like Nexplanon, NuvaRing, and Follistim AQ, as well as biosimilars and other medications that address health needs in multiple countries.
What are some notable products in Organon & Co.'s (OGN) portfolio?
Organon & Co. has a broad portfolio spanning several therapeutic areas. In women's health, key products include Nexplanon (contraceptive implant), NuvaRing (vaginal ring), and Follistim AQ (fertility treatment). The company also offers Jada for postpartum hemorrhage and Xaciato for bacterial vaginosis. Its biosimilars segment features immunology products like Brenzys, Renflexis, and Hadlima. Oncology offerings include Ontruzant and Aybintio. Cardiovascular products include cholesterol-lowering medications such as Zetia and Vytorin, as well as hypertension treatments Cozaar and Hyzaar. Respiratory products include Singulair and Dulera for asthma, and allergy medications like Nasonex and Clarinex. Dermatology brands include Vtama, Diprosone, and Elocon. Bone health is addressed with Fosamax, and pain management with non-opioid options like Arcoxia.